Growth funding MindImmune has recently closed a $30M extended Series A and secured a $5M strategic investment from the Alzheimer’s Drug Discovery Foundation, signaling strong investor confidence and capital availability to advance immune-driven therapies for neurodegenerative diseases.

Leadership expansion New CEO Isaac Stoner joined in late 2025 and a VP of Preclinical Development was appointed in 2025, indicating strategic leadership and added capability to accelerate product development and de-risk translational milestones.

Therapeutic focus The company concentrates on modulating the immune system to treat Alzheimer's and other neurodegenerative disorders, presenting opportunities for collaborations with partners seeking immune-oncology or neuroinflammation expertise, as well as contract research or platform licensing.

Financial health signals With reported revenue in the range of tens of millions and ongoing funding rounds, MindImmune presents a viable customer profile for high-touch CRO services, translational research collaborations, and strategic technology licensing discussions.

Regional positioning Headquartered in Providence, RI with a small-to-mid company size, MindImmune may value local or regional partnerships, talent sourcing, and pilot programs with nearby universities and biotech clusters to accelerate early-stage development and cost-efficient research efforts.